The kidney cancer drugs market was valued at USD 7.54 Billion in 2025 driven by rising global incidence of renal cell carcinoma (RCC) and increasing adoption of immuno-oncology therapies across 8 major markets. It is expected to grow at a CAGR of 6.30% during the forecast period of 2026-2035 and attain a market value of USD 13.89 Billion by 2035. Additionally, expanding treatment access across emerging markets, regulatory support for rare subtypes like translocation RCC, and the development of novel drug combinations that address resistance mechanisms are further strengthening the market’s growth prospects in the coming years.
Base Year
Historical Period
Forecast Period
Surging RCC cases in the US and Japan are set to boost demand for advanced kidney cancer therapies including drugs.
Combination therapies adoption for clear cell renal cell carcinoma treatment is a major market trend.
Oncorella-1 trial’s focus on dialysis-dependent RCC patients opens new market avenues for rare treatment-resistant cancer segments.
Kidney cancer, also known as renal cancer, originates in the kidneys and includes several types, with renal cell carcinoma (RCC) being the most common, accounting for about 90% of cases. Other types include transitional cell carcinoma, Wilms tumor (in children), and renal sarcoma. Treatment depends on the stage and type, ranging from surgery to targeted therapies and immunotherapies. Common drugs include tyrosine kinase inhibitors (like sunitinib and sorafenib), immune checkpoint inhibitors (like nivolumab), and combination regimens, which have improved survival rates for advanced and metastatic kidney cancer cases. The market is expected to grow at a CAGR of 6.30% during the forecast period of 2026-2035
Patient-Focused Research Boosting Market Growth
The increasing demand for precision therapies and patient-driven innovation is a significant market driver. For instance, in March 2025, Dana‑Farber and Broad Institute launched a new Count Me In patient‑partnered study targeting translocation RCC (tRCC), a rare aggressive subtype. By engaging patients directly for genomic and clinical data sharing, the initiative enhances understanding of tRCC’s molecular drivers and accelerates drug discovery pipelines. This collaborative model is expected to fast-track therapeutic development, expanding the kidney cancer drugs market through the forecast period with more targeted and effective treatment options.
Personalized Vaccine Breakthroughs to Enhance Kidney Cancer Drugs Market Value
The increasing focus on immunotherapies and adjuvant treatments is fueling market expansion. For instance, in February 2025, Dana‑Farber reported that nine stage III/IV clear cell RCC patients, treated with a personalized neoantigen vaccine following surgery, remained cancer‑free after 34.7 months and showed robust T‑cell responses (166‑fold increase). These early yet promising results signal a paradigm shift toward personalized vaccines in renal cell carcinoma management, likely driving demand for novel cancer drugs and enriching the pipeline with innovative immune-based therapies during the forecast period.
Major market trends include growing disease incidence, therapeutic innovations, and expanding clinical trials.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy
Market Breakup by Drug Class
Market Breakup by Indication
Market Breakup by Distribution Channel
Market Breakup by Region
Immune Checkpoint Inhibitors Dominating the Segment by Drug Class
Immune checkpoint inhibitors are expected to hold the largest market share due to their proven efficacy in treating advanced renal cell carcinoma and improving overall survival. These therapies, such as nivolumab and pembrolizumab, work by enhancing the immune system’s ability to target cancer cells. Their growing use in first-line and combination treatments, along with ongoing clinical advancements, positions this segment for strong growth. Increasing regulatory approvals and adoption in treatment guidelines further reinforce its leading role in the market.
United States and Japan Leading the Kidney Cancer Drugs Market by Region
The United States is poised to dominate the market due to its high disease burden, cutting-edge immunotherapy approvals, and strong oncology R&D ecosystem. It is expected to see nearly 81,000 new kidney cancer cases in 2025, driving drug demand. Japan is expected to follow closely, supported by a rapidly aging population and high healthcare spending. In 2022, Japan experienced 21,207 new cases of kidney cancer, highlighting the increasing burden of the market. Early integration of combination therapies and robust post-marketing surveillance also contributes to Japan’s growing influence in the kidney cancer treatment landscape.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Active Biotech AB, founded in 1998 and headquartered in Lund, Sweden, is a biotechnology company focused on the development of immunomodulatory drugs for the treatment of cancer and inflammatory diseases. In the kidney cancer drugs market, the company is recognized for developing laquinimod and tasquinimod, both aimed at targeting tumor growth and microenvironments. With a strong emphasis on innovative therapies, Active Biotech continues to contribute to the advancement of novel treatments in the oncology space, including renal cell carcinoma.
Established in 1980 and based in Thousand Oaks, California, Amgen is a global biopharmaceutical leader known for its pioneering work in biotechnology and oncology. The company’s kidney cancer portfolio includes the development and marketing of targeted therapies, such as tivozanib and investigational agents focused on angiogenesis inhibition and immunotherapy combinations. Through extensive R&D efforts and strategic collaborations, Amgen continues to expand its oncology pipeline, aiming to address unmet clinical needs in renal cell carcinoma and related cancers.
Headquartered in Leverkusen, Germany, and founded in 1863, Bayer AG is a life sciences giant with a robust pharmaceuticals division, including oncology. In the kidney cancer space, Bayer is known for developing drugs like Nexavar (sorafenib) and Stivarga (regorafenib), both tyrosine kinase inhibitors approved for various cancers, including advanced renal cell carcinoma. The company continues to invest in innovative therapies and clinical trials to enhance treatment outcomes and maintain its strong foothold in the kidney cancer drugs market.
Cipla Limited, founded in 1935 and headquartered in Mumbai, India, is a leading global pharmaceutical company with a strong presence in generics and specialty medicines. In the kidney cancer segment, Cipla offers cost-effective generic versions of key cancer therapeutics, including sorafenib, enhancing access to affordable treatment options. The company actively supports oncology care across emerging markets and is committed to expanding its oncology portfolio through partnerships, R&D, and biosimilar launches to address the growing burden of renal cancers.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include F. Hoffmann-La Roche AG, GSK plc, Novartis AG, Pfizer Inc., Astellas Pharma, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Merck & Co., Inc., among others.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy |
|
| Breakup by Drug Class |
|
| Breakup by Indication |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share